Hercules Capital, Inc. (HTGC) currently offers an attractive 11.5% dividend yield and trades below its historical valuation, presenting a good entry point for investors. Its floating-rate loan portfolio is well-positioned to benefit from expected near-term interest rate hikes, supporting earnings growth. The company demonstrates consistent outperformance compared to peers, strong risk management, and significant insider ownership, which reinforce its competitive advantages. Consequently, the stock rating has been upgraded from Hold to Buy, making it appealing for income-focused investors seeking robust fundamentals and discounted valuation.
Hercules Capital offers an 11.5% dividend yield and trades below historical valuation. For readers following Financials, here is Pluang's market snapshot as of Oct 20, 2026 02:12 WIB: Of 142 priced US Financials stocks, 28 rose and 113 fell today. Deutsche Bank AG (DB) traded at USD 31.64 with a 1-day change of -2.86%, Coinbase Global, Inc. (COIN) at USD 168.68 down 2.59%, and Wells Fargo & Co (WFC) at USD 81.75 down 2.53%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
